1 - 10 of 33 articles
This month, “The AJT Report” examines a new generation of drugs to treat hepatitis C that could change the landscape of liver transplantation. We also take a look at the National Living Donor Assistance Center, and review the CDC's quest for a national transplant safety network.
Screening of organ donors for HTLV‐1/2 infection has advantages and disadvantages that must be weighed, and rational decisions will require new evidence. See minireview by Kaul et al on page 207.
New data suggest that the pleiotropic cytokine interleukin‐6 may be a key contributor to allograft fibrosis through a complex interaction with connective tissue growth factor (CTGF), a downstream effector of TGF‐beta. See article by Booth et al on page 220.
Hepatopulmonary syndrome is potentially no longer a contraindication to liver transplantation when the required clinical support is delivered. See article by Gupta et al on page 354.
How do we balance the trade‐offs between reduced rates of allograft rejection and other morbidities such as renal dysfunction, myelosuppression and non‐specific graft failure? See article by Teuteberg et al on page 382.
Organ Procurement and Transplant Network (OPTN) policy currently requires the testing of all potential organ donors for human T‐cell lymphotrophic virus (HTLV)‐1/2. Most Organ Procurement Organizations (OPO) use the Abbott HTLV‐I/HTLV‐II Enzyme Immunoassay (EIA). This assay will no longer be...
Although well‐recognized for their sentinel role and, when activated, their immunostimulatory function, bone marrow‐derived dendritic cells (DC) possess inherent tolerogenic (tol) ability. Under quiescent conditions, these cells maintain central and peripheral self tolerance. When appropriately...
Cardiac transplantation is an effective treatment for multiple types of heart failure refractive to therapy. Although immunosuppressive therapeutics have increased survival rates within the first year posttransplant, chronic rejection (CR) remains a significant barrier to long‐term graft...
Calcineurin inhibitors (CNI) are powerful immunomodulatory agents that produce marked renal dysfunction due in part to endothelin‐1‐mediated reductions in renal blood flow. Ligand‐stimulated Gq protein signaling promotes the contraction of smooth muscle cells via phospholipase Cβ‐mediated...
Thrombomodulin (TBM) is an important vascular anticoagulant that has species specific effects. When expressed as a transgene in pigs, human (h)TBM might abrogate thrombotic manifestations of acute vascular rejection (AVR) that occur when GalT‐KO and/or complement regulator transgenic pig organs...
Read and print from thousands of top scholarly journals.
Continue with Facebook
Log in with Microsoft
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Sign Up Log In
To subscribe to email alerts, please log in first, or sign up for a DeepDyve account if you don’t already have one.
To get new article updates from a journal on your personalized homepage, please log in first, or sign up for a DeepDyve account if you don’t already have one.